IP Library Granted Patent US 7,745,158
Granted Patent B2
US 7,745,158 · App. 11/302,975 · Granted Jun 29, 2010

Detection of secreted aspartyl proteases from

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,745,158
App. No.
11/302,975
Granted
Jun 29, 2010
Kind
B2
Abstract

Methods and devices for the detection of proteins secreted by the hyphal growth form of Candida species are disclosed. The disclosed devices may constitute a method for the diagnosis of acute or chronic infections, including candidiasis, caused by microorganisms of the species Candida , such as C. albicans , for example. The devices of the present invention incorporate antibodies specific to secreted aspartyl protease proteins whose expression is upregulated upon the conversion of the Candida species from the commensal to the pathogenic form. The antibodies may be used in assays to allow the diagnosis of candidal infections and disease conditions. Either monoclonal antibodies or polyclonal antibodies may be used, and in the case of the monoclonals, the specific epitopes of the SAP protein may be detected as well as the SAP protein itself.

Claims (20)

1. A diagnostic test kit for detecting a secreted aspartyl protease protein within a test sample, the diagnostic test kit comprising:

a lateral flow heterogeneous assay device comprising a fluidic medium, the fluidic medium defining a detection zone within which is immobilized a receptive material, wherein a test sample applied to the lateral flow assay device flows to the detection zone, and the detection zone generates a detection signal that corresponds to the presence or absence of a secreted aspartyl protease protein; and

a detection probe conjugated with a binding member;

wherein the receptive material, the binding member, or both contain a first antibody that is capable of specifically binding to the secreted aspartyl protease protein.

2. The diagnostic test kit of claim 1 , wherein the receptive material contains the first antibody.

3. The diagnostic test kit of claim 2 , wherein the binding member contains a second antibody that specifically binds to the secreted aspartyl protease protein.

4. The diagnostic test kit of claim 3 , wherein the first antibody is a monoclonal antibody that specifically binds to a first epitope of the secreted aspartyl protease protein and the second antibody is a monoclonal antibody that specifically binds to a second epitope of the secreted aspartyl protease protein.

5. The diagnostic test kit of claim 1 , wherein the binding member contains the first antibody.

6. The diagnostic test kit of claim 1 , wherein the first antibody is a monoclonal antibody.

7. The diagnostic test kit of claim 1 , wherein the first antibody is a polyclonal antibody.

8. The diagnostic test kit of claim 1 , wherein the fluidic medium is a porous membrane.

9. The diagnostic test kit of claim 1 , wherein the first antibody has been developed against a recombinant secreted aspartyl protease protein or an immunogenic fragment thereof.

10. The diagnostic test kit of claim 9 , wherein the first antibody has been developed by a hybridoma cell that has been generated through fusion of a human tumor cell with a cell from an animal immunized with the recombinant secreted aspartyl protease protein or an immunogenic fragment thereof.

11. The diagnostic test kit of claim 1 , wherein the diagnostic test kit is capable of detecting infection by Candida albicans.

12. The diagnostic test kit of claim 1 , the lateral flow assay device further comprising an absorbent pad located downstream from the detection zone.

13. The diagnostic test kit of claim 1 , the lateral flow assay device further comprising a conjugate pad located upstream of the detection zone.

14. The diagnostic test kit of claim 13 , the conjugate pad carrying the detection probe in a dehydrated form, the detection probe being free to migrate upon rehydration with a test sample.

15. The diagnostic test kit of claim 1 , the lateral flow assay device further defining an indicator zone.

16. The diagnostic test kit of claim 1 , the lateral flow assay device further defining a calibration zone.

17. The diagnostic test kit of claim 1 , wherein the conjugated detection probes or complexes thereof are separated from the test sample as the test sample flows across or through the lateral flow assay device.

Assignments (2)
NAME CHANGE Recorded Feb 3, 2015
From: KIMBERLY-CLARK WORLDWIDE, INC.
To: KIMBERLY-CLARK WORLDWIDE, INC.
Reel/Frame 034880/0704 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2006
From: PHILLIPS, ERICA M.; DIGIAMMARINO, ENRICO L.; MCGRATH, KEVIN P.
To: KIMBERLY-CLARK WORLDWIDE, INC.
Reel/Frame 017738/0678 →